The DOJ backs Medicare price negotiations amidst a Novartis lawsuit, while President Trump vows to lower U.S. drug costs.

The next round of Medicare's historic drug price negotiations could save billions for seniors taking medications like Ozempic ...

We now have a glimpse behind the curtain of how Medicare arrives at so-called maximum fair prices of prescription drugs it ...

CMS recently issued a statement saying that it's continuing the Medicare Drug Price Negotiation Program but is leaving the ...

Trump could either weaken the negotiations in a way that benefits the pharmaceutical industry, or try to achieve even deeper ...

The U.S. Department of Justice has filed an appeals court brief supporting the right of Medicare officials to negotiate ...

China’s share of the global drug development pipeline grew from 3% in 2013 to 28% in 2023, positioning China as the ...

The Centers for Medicare and Medicaid Services (CMS) and pharmaceutical drug manufacturers are gearing up for the second ...

Explore how Medicare drug price negotiations under the Inflation Reduction Act could evolve with the Trump administration. Read more here.

The start of Donald Trump’s second presidency and Republican control in the 119th Congress raises questions about the future ...

If big pharma was hoping that there would not be drug price negotiations under President Trump, they seem to have had their hopes dashed. That ...